Skip to main content
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

PR Newswire - Mon Aug 14, 2023

HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma

Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype

Read more at prnewswire.com